טוען...
Alemtuzumab improves contrast sensitivity in patients with relapsing–remitting multiple sclerosis
BACKGROUND: Alemtuzumab is a monoclonal antibody directed against CD52 that depletes T and B lymphocytes. OBJECTIVE: To evaluate the treatment effect of alemtuzumab on low-contrast vision in relapsing–remitting multiple sclerosis (RRMS) patients. METHODS: This was a pre-defined exploratory analysis...
שמור ב:
| Main Authors: | , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
SAGE Publications
2013
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3807733/ https://ncbi.nlm.nih.gov/pubmed/23459567 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1352458513475722 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|